The currently established nomenclature for psychotropic drugs is outdated and no longer reflects the progress of neuroscience. In response to this situation, the Neurosci-ence-based Nomenclature (NbN) was developed: A system for the classification of psy-chotropic drugs, which brings important advantages for patients, clinicians, and re-searchers. The German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) supports the introduction of the NbN in care, science, and teaching.  

The DGPPN actively campaigns for the participation of people with mental illness in society and against their stigmatization. We are committed to respecting the dignity and the right of self-determination of service users and support them irrespective of gender, skin colour, religion or social background. In the light of the history of psychiatry, DGPPN is committed to the principles of diversity and inclusion.

The DGPPN is the largest scientific medical association focussing on mental health in Germany. It pools the competence of 9000 doctors and scientists in the fields of psychiatry, psychotherapy and psychosomatics who work in university and non-university hospitals, in office-based practices and in research.

The world of work is changing: digitalisation and globalisation are constantly increasing the demands on workers and require maximum flexibility. What these developments ultimately mean for the individual is not yet fully clear. What is clear, however, is that the increasing interconnectedness of people and machines will fundamentally change the way we work and the associated mental stress.